Prot #MCC-001: Phase 2 Study of aNK (Activated NK-92, Natural Killer Cells) Infusions in Combination with ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)